Bright Minds Biosciences (DRUG) Liabilities and Shareholders Equity (2021 - 2026)
For the quarter ending Q1 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $227.8 million, compared with a TTM value of $293.6 million through Mar 2026, up 6460.83%, and an annual FY2025 reading of $61.3 million, up 1270.81% over the prior year.
Bright Minds Biosciences (DRUG) has disclosed Liabilities and Shareholders Equity for 3 consecutive years, with $227.8 million as the latest value for Q1 2026.
- Liabilities and Shareholders Equity reached $227.8 million in Q1 2026 per DRUG's latest filing, up from $61.3 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $227.8 million in Q1 2026 and bottomed at $4.5 million in Q3 2024.
- Average Liabilities and Shareholders Equity over 3 years is $97.9 million, with a median of $61.3 million recorded in 2025.
- The widest YoY moves for Liabilities and Shareholders Equity: up 1270.81% in 2025, down 1270.81% in 2025.
- Bright Minds Biosciences' Liabilities and Shareholders Equity stood at $4.5 million in 2024, then skyrocketed by 1270.81% to $61.3 million in 2025, then soared by 271.32% to $227.8 million in 2026.
- Per Business Quant, the three most recent readings for DRUG's Liabilities and Shareholders Equity are $227.8 million (Q1 2026), $61.3 million (Q3 2025), and $4.5 million (Q3 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 40.87 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 23.64 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Bright Minds Biosciences | 464.72 Mn | 405.19 Mn | - | 227.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 227.78 Mn |
| Dec 31, 2025 | 65.17 Mn |
| Sep 30, 2025 | 61.34 Mn |
| Jun 30, 2025 | 37.89 Mn |
| Mar 31, 2025 | 39.35 Mn |
| Dec 31, 2024 | 41.80 Mn |
| Sep 30, 2024 | 4.47 Mn |
| Jun 30, 2024 | 4.59 Mn |
| Mar 31, 2024 | 4.85 Mn |
| Dec 31, 2023 | 5.06 Mn |
| Sep 30, 2023 | 5.13 Mn |
| Jun 30, 2023 | 6.30 Mn |
| Mar 31, 2023 | 7.39 Mn |
| Dec 31, 2022 | 8.51 Mn |
| Sep 30, 2022 | 9.27 Mn |
| Jun 30, 2022 | 6.92 Mn |
| Mar 31, 2022 | 9.29 Mn |
| Dec 31, 2021 | 12.23 Mn |
| Sep 30, 2021 | 15.92 Mn |